The SafeSEQ NSCLC panel is a clinical grade, ultra-sensitive liquid biopsy solution for the identification of gene mutations, shown in the table below, associated with Non-Small Cell Lung Cancer (NSCLC).
The SafeSEQ NSCLC panel delivers equivalent performance with broader genomic coverage than testing with OncoBEAM™ digital PCR (dPCR). Further, the assay demonstrates ultra-sensitive detection of low-frequency mutations, with a calling threshold of 5 MM (0.025% MAF for 20,000 GE DNA input), while specificity remains very high.
SafeSEQ and OncoBEAM testing demonstrates 99.6% overall agreement for the detection of mutations in EGFR, KRAS, and BRAF, with a strong positive correlation between MAF values across a broad dynamic range, as seen in the figure above.
- Sloane, H; Sathyanarayan, P.; Edelstein, D., Jones, F.; Preston, J; Wu, S; Los, J.; Duchstein, L.; Fredebohm, J.; Wichner, K.; Heim, D.; et al. Clinical evaluation of NGS-based liquid biopsy genotyping in non-small cell lung cancer (NSCLC) patients. Cancer Res July 1 2021 (81) (13 Supplement) LB053; DOI: 10.1158/1538-7445.AM2021-LB053